MARKET

SYBX

SYBX

Synlogic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.170
-0.010
-0.31%
After Hours: 3.230 +0.06 +1.89% 17:28 09/24 EDT
OPEN
3.150
PREV CLOSE
3.180
HIGH
3.308
LOW
3.150
VOLUME
367.27K
TURNOVER
--
52 WEEK HIGH
5.11
52 WEEK LOW
1.780
MARKET CAP
166.02M
P/E (TTM)
-2.2829
1D
5D
1M
3M
1Y
5Y
Hot Stocks: DELL, CRM rally on forecasts; JOBY, ROKU get lift from analyst notes; SYBX falls on stock sale
Optimistic outlooks sent a couple of big-name stocks higher in Thursday's midday trading. Both Dell (NYSE:DELL) and Salesforce (NYSE:CRM) rallied on well-received long-term forecasts. Analyst comments provided another major theme
Seekingalpha · 2d ago
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Amplitude Healthcare Acquisition Corporation (NASDAQ: AMHC) rose 61.8% to $16.55 in pre-market trading. The company disclosed that shareholders approved the business combination with Jasper Therapeutics.
Benzinga · 2d ago
Microbiome Therapeutics Market Research By Production, Revenue, Sales Value, Industry Trends, Impact Factors And SWOT Analysis 2029
Research Nester released a report titled which delivers a detailed overview of the global microbiome therapeutics market in terms of market segmentation by application and by region.
AmericaNewsHour · 2d ago
Synlogic Late Wednesday Priced 15M Share Public Offering of Common Stock @$3.00/Share
Synlogic (NASDAQ: SYBX) announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $3.00 per share.
Benzinga · 2d ago
Top Premarket Decliners
MT Newswires · 2d ago
Synlogic Prices Common Stock Offering at $3 Per Share
MT Newswires · 2d ago
BRIEF-Synlogic Announces Proposed Public Offering Of Common Stock
reuters.com · 2d ago
Synlogic Announces Proposed Public Offering of Common Stock
/PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock ...
PR Newswire - PRF · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SYBX. Analyze the recent business situations of Synlogic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SYBX stock price target is 10.00 with a high estimate of 15.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 103
Institutional Holdings: 40.30M
% Owned: 76.95%
Shares Outstanding: 52.37M
TypeInstitutionsShares
Increased
16
2.96M
New
12
9.37M
Decreased
17
1.22M
Sold Out
6
49.99K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Peter Barrett
President/Chief Executive Officer/Director
Aoife Brennan
Chief Financial Officer
Gregg Beloff
Finance Director/Senior Vice President
Daniel Rosan
Chief Operating Officer
Antoine Awad
Vice President
Jamie Austin
Other
Caroline Kurtz
Independent Director
Michael Burgess
Independent Director
Michael Heffernan
Independent Director
Patricia Hurter
Independent Director
Lisa Kelly-Croswell
Independent Director
Nick Leschly
Independent Director
Edward Mathers
Independent Director
Richard Shea
No Data
  • All
  • Financials
  • Insiders
More
About SYBX
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the drug discovery and development of Synthetic Biotic medicines. Its product pipeline includes Synthetic Biotic medicines for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria. The Company's lead product candidate includes SYNB1618, which is an oral therapy for the treatment of PKU. Its other product candidate SYNB8802 is developed for the treatment of Enteric Hyperoxaluria. The Company developed Synthetic Biotic medicines to treat certain cancers that are designed to modify the tumor microenvironment, activate the immune system and result in tumor reduction. It is developing SYNB1891 for the treatment solid tumors and lymphoma. The Company is conducting Phase II clinical trial with SYNB1618.

Webull offers kinds of Synlogic Inc stock information, including NASDAQ:SYBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SYBX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SYBX stock methods without spending real money on the virtual paper trading platform.